Cervical cancer is the second most frequent cancer among women between 15 and 44 years of age.
Union Minister Dr Jitendra Singh announces India’s first indigenously developed vaccine, “CERVAVAC” for the prevention of cervical cancer
According to WHO (World Health Organization), India has the fifth largest cases of cervical cancer in the world.
Around 67,000 women die of cervical cancer, and around 1,23 cases are diagnosed yearly.
SII says Cervavac, the Indian HPV vaccine to treat cervical cancer in women will be both affordable and accessible.
The Quadrivalent Human Papillomavirus vaccine (qHPV), which is India's first vaccine against HPV,
Cervical cancer occurs in the cells of the cervix — the lower part of the uterus. It's mostly caused by various strains of HPV, which is sexually transmitted.
The DCGI's approval for Cervavac comes following recommendation by the Subject Expert Committee (SEC) . The government advisory panel NTAGI had recently also approved the qHPV after reviewing the clinical trial data.